Aligos Therapeutics, Inc. (ALGS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ALGS currently has 6.19M outstanding shares. with significant dilution risk as 208M authorized shares could dilute existing holders by 3363.0%. The company has significantly diluted shareholders by 82.04% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 6.2M shares outstanding |
6.2M | 210M |
| Nov 06, 2025 |
10-Q filing | 6.2M shares outstanding |
6.2M | 210M |
| Aug 06, 2025 |
10-Q filing | 6.2M shares outstanding |
6.2M | 210M |
| May 06, 2025 |
10-Q filing | 6.1M shares outstanding |
6.1M | 210M |
| Mar 27, 2025 |
S-3 filing: This S-3 filing describes the resale of up to 6,245,475 shares of common stock by selling securityholders. |
6.3M | 210M |
| Mar 10, 2025 |
10-K filing | 6.3M shares outstanding |
6.3M | 200M |
| Nov 06, 2024 |
10-Q filing | 3.5M shares outstanding |
3.5M | 200M |
| Nov 06, 2024 |
S-3 filing: Aligos Therapeutics, Inc. may offer and sell up to $400,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
77M | 200M |
| Aug 06, 2024 |
10-Q filing | 76.8M shares outstanding |
77M | 200M |
| May 07, 2024 |
10-Q filing | 75.0M shares outstanding |
75M | 200M |
| Mar 12, 2024 |
10-K filing | 72.6M shares outstanding |
73M | 200M |
| Nov 17, 2023 |
S-3 filing: This S-3 filing relates to the resale of up to 168,725,925 shares of common stock by selling securityholders. |
72M | 200M |
| Nov 02, 2023 |
10-Q filing | 71.8M shares outstanding |
72M | 33M |
| Aug 03, 2023 |
10-Q filing | 43.2M shares outstanding |
43M | 33M |
| May 04, 2023 |
10-Q filing | 42.9M shares outstanding |
43M | 33M |
| Mar 09, 2023 |
10-K filing | 39.8M shares outstanding |
40M | 33M |
| Nov 02, 2022 |
10-Q filing | 42.8M shares outstanding |
43M | 33M |
| Aug 04, 2022 |
10-Q filing | 39.7M shares outstanding |
40M | 33M |
| May 04, 2022 |
10-Q filing | 39.6M shares outstanding |
40M | 33M |
| Mar 10, 2022 |
10-K filing | 39.6M shares outstanding |
40M | 33M |
| Nov 04, 2021 |
10-Q filing | 39.5M shares outstanding |
40M | 33M |
| Nov 04, 2021 |
S-3 filing: Aligos Therapeutics, Inc. files an S-3 to offer and sell up to $400,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
43M | 33M |
| Aug 05, 2021 |
10-Q filing | 42.6M shares outstanding |
43M | 7.7M |
| Jun 28, 2021 |
S-1 filing: The company is offering 4,000,000 shares of common stock in an S-1 filing, with an additional 600,000 shares available to underwriters, with the intention of using the proceeds to fund clinical advancement and research of their drug candidates. |
38M | 7.7M |
| May 10, 2021 |
10-Q filing | 38.2M shares outstanding |
38M | 3.1M |
| Mar 23, 2021 |
10-K filing | 38.1M shares outstanding |
38M | 3.1M |
| Nov 25, 2020 |
10-Q filing | 38.1M shares outstanding |
38M | 3.1M |
| Oct 09, 2020 |
S-1/A filing: This is an S-1/A filing. It details recent sales of unregistered securities, including common stock, convertible promissory notes, Series A, B-1, and B-2 convertible preferred stock, and grants of stock options and awards. |
N/A | 3.1M |
| Sep 25, 2020 |
S-1 filing: This S-1 filing details recent sales of unregistered securities, including common stock, convertible promissory notes, Series A and Series B-1 convertible preferred stock, and stock options/awards to employees, directors, and consultants. |
N/A | 29M |